News

The oral Impavido has been approved for the three main types of leishmaniasis, including visceral leishmaniasis, cutaneous leishmaniasis and mucosal leishmaniasis. The drug is intended for patients 12

Concordia CEO Mark Thompson noted that the acquisition of Donnatal represents an important advancement in the execution of the company’s legacy product strategy, providing substantial and sustainable revenue

A manufacturing agreement that covers all aspects of the production of the encapsulated live cells has been signed by Nuvilex and Austrianova. An initial payment has been made

MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular

The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time. The ENCHANT-1

The acquisition adds to the comprehensive biotechnology services that AIBioTech currently provides to its clients by performing assessments that examine the effects of drugs, chemicals, biologics, and other

As part of the deal, Eisai will work with LSTM and UoL to discover and develop new drug candidates that efficiently eliminate the bacteria Wolbachia. LSTM is a

Andexanet alfa, which secured breakthrough therapy designation from the US FDA, is being developed as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated

As part of the deal, arGEN-X has licensed the firm’s POTELLIGENT CHOK1SV Cell Line Technology for use in the development of ARGX-110, a proprietary antibody in its pipeline.